CliffBio
small molecule

VIZIMPRO

DACOMITINIB

Loss of exclusivitySeptember 2032latest FDA-listed patent expiry
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameVIZIMPRO
Active ingredientDACOMITINIB
Strength30MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2018
Marketing statusRX

Listed patents

PatentExpiresType
7772243September 2032substance, product
10603314February 2026use U-3337
10596162February 2026use U-3338

More from Pfizer

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

VIZIMPRO patent cliff — loss of exclusivity September 2032 | CliffBio